
2016 Standard Formulary





## At-A-Glance: 2016 Standard Formulary Changes

## **NEW DRUG CLASSES AFFECTED**

- Antiobesity, Oral
- **Antipsychotics**
- Dermatology, Actinic Keratosis
- **IBS** Constipation

- Opioid Induced Constipation
- **Phosphate Binders**
- Rosacea
- SNRI

**EXISTING DRUG CLASSES WITH NEW EXCLUSIONS** 

- ADHD
- **Anticholinergics**
- Antiviral
- ARB
- Calcium Channel **Blockers**

- Dermatology, Corticosteroid
- Erectile Dysfunction
- GLP-1
- Multiple Sclerosis

- Partial Opioid **Agonists**
- SGLT2
- Testosterone Replacement, **Androgens**
- Viscosupplements

**Expected book of business disruption 0.9%** 

## **2016 List of Template Exclusions**

| <u>CLASS</u>                                     | PRODUCTS   | <u>CLASS</u>                       | PRODUCTS  | <u>CLASS</u>                                  | PRODUCTS              |
|--|--|------------------------------------|---|---|-----------------------|
| ADHD   | Intuniv (MSB)  | Calcium<br>Channel<br>Blockers*    | Cardizem (MSB Only), Cardizem<br>CD (MSB Only), Cardizem LA<br>(all Brands and all Generics,<br>which includes Matzim LA) | Opioid Induced<br>Constipation<br>(New Class) | Relistor              |
| Anticholinergics                                 | Incruse Ellipta  | Dermatology –<br>Corticosteroid*   | Clobex &<br>Clobetasol 0.05 Spray   | Phosphate Binders<br>(New Class)              | Fosrenol              |
| Dermatology,<br>Actinic Keratosis<br>(New Class) | Carac Cream &<br>Fluorouracil 0.5%<br>Cream                      | Erectile<br>Dysfunction            | Viagra  | Rosacea<br>(New Class)                        | Noritate              |
| Antiviral  | Valcyte (MSB)  | GLP-1                              | Bydureon  | SNRI<br>(New Class)                           | Cymbalta (MSB)        |
|  |  |                                    |   |   |                       |
| Antiobesity Oral<br>(New Class)                  | Qsymia   | IBS<br>Constipation<br>(New Class) | Amitiza   | SGLT2   | Invokana/Invokamet    |
|  |  |                                    |   |   | Farxiga Added<br>Back |
|  | Abilify oral tablets,<br>solution, and ODT<br>formulations (MSB) | Multiple<br>Sclerosis              | Avonex, Extavia, Plegridy   | Testosterone<br>Replacement,<br>Androgens     | Fortesta              |
| Antipsychotics<br>(New Class)                    |  |                                    | Rebif Added Back  |   |                       |
|  | Diovan (MSB),<br>Exforge/HCT (MSB)                               | Partial Opioid<br>Agonists         | Zubsolv   | Viscosupplements                              | Monovisc              |
| ARB  |  |                                    | Suboxone Film Added Back  |   |                       |

- Specialty: As new specialty products launch, all existing products in the class will be re-evaluated to determine appropriate formulary placement and potentially be excluded, not listed or added back to the formulary.
- Hepatitis C: As new hepatitis C products launch, all existing products in the class will be re-evaluated to determine appropriate formulary placement and potentially be excluded, not listed or added back to the formulary.

This slide contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.